Fianlimab + cemiplimab versus pembrolizumab in first-line metastatic melanoma. A four-arm Phase 3 head-to-head testing whether adding LAG-3 to PD-1 covers a second step in the immune cycle, with a cemiplimab monotherapy comparison arm that makes this the cleanest possible test of the LAG-3 attribution.
Fianlimab is a LAG-3 inhibitor. Unlike TIGIT — which engages T cells at the same effector encounter step as PD-1 — LAG-3 addresses a structurally different step. LAG-3 operates on antigen presentation and detection, earlier in the immune cycle. PD-1 operates downstream, on effector engagement at the synapse. The two targets are at different steps, not different drugs at the same step.
RELATIVITY-047 (relatlimab + nivolumab vs nivolumab in melanoma) already demonstrated a ~10 percentage point ORR advantage from this same coverage extension — from one step covered to two. The framework predicts that fianlimab + cemiplimab versus pembrolizumab will reproduce that pattern, because the structural change is identical: PD-1 alone (one step) versus LAG-3 + PD-1 (two steps).
What makes Harmony Melanoma unusually clean is its four-arm design. The trial includes Arm A (fianlimab dose 1 + cemiplimab), Arm A1 (fianlimab dose 2 + cemiplimab), Arm B (pembrolizumab + placebo), and Arm C (cemiplimab + placebo). The cemiplimab monotherapy arm is the critical test: if cemiplimab monotherapy is clinically equivalent to pembrolizumab, then any benefit observed in the fianlimab combination arms can be unambiguously attributed to the LAG-3 step rather than to switching the underlying PD-1 antibody. This is the cleanest test of the LAG-3 attribution available in any current Phase 3 trial.
Each row below is a falsifiable claim with a value range. If the trial reports out within these ranges, the prediction is a hit. If it reports outside them in the named direction, the prediction is a miss.
| Metric | Predicted value |
|---|---|
| PFS hazard ratio (fianli + cemi vs pembro) | 0.70–0.80 |
| ORR experimental (fianlimab + cemiplimab) | ~58% |
| ORR control (pembrolizumab) | ~33.7% |
| CR rate, experimental arm | 20–25% |
| Cemiplimab monotherapy arm vs pembro | Clinically equivalent |
| LAG-3 high subgroup | Largest benefit |
The critical test: the cleanest test is the comparison (cemi mono ≈ pembro) AND (fianlimab + cemi > both). That pattern proves the benefit comes from adding the LAG-3 step, not from switching PD-1 antibodies. If cemiplimab monotherapy beats pembrolizumab by more than 3pp, the antibody-switching effect is real and the LAG-3 attribution is contaminated. If the fianlimab combination fails to beat pembrolizumab by at least 5pp on PFS HR, the structural prediction that LAG-3 addresses a separate step in melanoma is wrong.
The structural reasoning behind the call — which steps in the immune cycle each drug covers, where the prediction would break, what it means for the design of follow-on trials in adjacent indications — is in the full report. The full report also includes the framework's per-metric reasoning for each row in the table above and the structural mapping for the trial's arms.
Fill the form to start the purchase. We reply within two business days with the price, scope, and a Stripe invoice. The full report is delivered as a PDF on payment.
* Trial cost estimate: ~1,590 patients × $40K median per patient (oncology Phase 3, US sites, Moore et al. 2018 cross-sectional analysis of 2015–2017 trials). Order-of-magnitude only — actual trial cost is not publicly disclosed.